Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
1. A method of treating a subject with a metabolic disorder, the method comprising administering to the subject a therapeutically effective amount of an antigen binding protein that specifically binds to a polypeptide comprising amino acids 1-139 of human Gastric Inhibitory Peptide Receptor (“GIPR”), wherein said antigen binding protein is an antibody and is an antagonist of GIPR.
2. The method of claim 1 , wherein said metabolic disorder is a disorder of glucose metabolism.
3. The method of claim 2 , wherein said glucose metabolism disorder comprises hyperglycemia and wherein said administering reduces plasma glucose in said subject.
4. The method of claim 2 , wherein said glucose metabolism disorder comprises hyperinsulinemia and wherein said administering reduces plasma insulin in said subject.
5. The method of claim 2 , wherein said glucose metabolism disorder comprises glucose intolerance and wherein said administering increases glucose tolerance in said subject.
6. The method of claim 2 , wherein said disorder of glucose metabolism comprises insulin resistance and wherein said administering decreases insulin resistance in said subject.
7. The method of claim 2 , wherein said glucose metabolism disorder comprises diabetes mellitus.
8. The method of claim 2 , wherein said subject is obese.
9. The method of claim 8 , wherein said administering reduces body weight in said subject.
10. The method of claim 8 , wherein said administering reduces body weight gain in said subject.
11. The method of claim 8 , where said administering reduces fat mass in said subject.
12. The method of claim 8 , wherein said disorder of glucose metabolism comprises insulin resistance and wherein said administering reduces insulin resistance in said subject.
13. The method of claim 8 , wherein said subject has increased liver steatosis, and wherein said administering reduces liver steatosis in said subject.
14. The method of claim 8 , wherein said subject has increased liver fat content, and wherein said administering reduces liver fat content in said subject.
15. The method of claim 1 , wherein said subject is a mammal.
16. The method of claim 1 , wherein said subject is human.
17. The method of claim 1 , wherein said administering is by parenteral injection.
18. The method of claim 1 , wherein said administering is by subcutaneous injection.